Andere talen Bristol-Myers Squibb Company Sao Paulo

Aandelen

BMYB34

BRBMYBBDR000

Beurs gesloten - Sao Paulo Andere beurzen 17:48:13 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
233 ^BRL	+1,74%		+2,42%	-6,77%

27/06	Purple Biotech zegt dat tussentijdse gegevens van onderzoek naar alvleesklierkanker veelbelovend zijn	MT
26/06	2seventy bio verkoopt Hemofilie A-kandidaat, genbewerkingstechnologie aan Novo Nordisk; aandelen stijgen na de uren	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26/06
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	20/06
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur